Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).

M, Banach; PE, Penson; M, Vrablik; M, Bunc; K, Dyrbus; J, Fedacko; D, Gaita; M, Gierlotka; Z, Jarai; SL, Magda; E, Margetic; R, Margoczy; A, Durak-Nalbantic; P, Ostadal; D, Pella; M, Trbusic; CA, Udroiu; C, Vlachopoulos; D, Vulic; Z, Fras; D, Dudek; Ž, Reiner

doi:10.1016/j.phrs.2021.105499

Public

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).

Shared by NobleBlocks on Feb 17, 2021 • 12:00 AM UTC

Authors:

Banach M

Penson PE

Vrablik M

Abstract

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound pr...

Subject

Safety

Effectiveness

Combination therapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!